Sai Parenteral's

Why is Sai Parenterals Ltd falling/rising?

As of 14-Jun, Sai Parenterals Ltd's stock price is at Rs. 567.15, having risen 1.7% today and 20.38% over the past month, significantly outperforming the Sensex. Despite a decline in investor participation, the stock is on a bullish trend, reaching a new all-time high of Rs. 597.15.

As of 14-Jun, Sai Parenterals Ltd's stock price is rising, currently at Rs. 567.15, reflecting an increase of Rs. 9.5 or 1.7%. The stock has shown strong performance over the past week, with a gain of 3.91%, and an impressive 20.38% increase over the past month, significantly outperforming the Sensex, which rose only 1.30% in the same period. <BR><BR>Today, the stock reached a new 52-week and all-time high of Rs. 597.15, marking a substantial intraday increase of 7.08%. It opened with a gain of 2.73% and has been on a consecutive upward trend for the last two days, accumulating a total return of 3.32%. Additionally, Sai Parenterals Ltd is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong bullish trend.<BR><BR>However, it is worth noting that there has been a decline in investor participation, with delivery volume dropping by 37.23% compared to the 5-day average. Despite this, the stock remains liquid enough for trading, suggesting that the current rise is supported by positive market sentiment and performance metrics rather than high trading volume.

Which are the latest news on Sai Parenteral's?

What does Sai Parenteral's do?

Sai Parenterals Ltd is a small-cap company in the Pharmaceuticals & Biotechnology industry, specializing in parenteral products. As of March 2026, it reported net sales of ₹57 Cr and a net profit of ₹10 Cr, with a market cap of ₹2,479 Cr.

Overview: <BR>Sai Parenterals Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History: <BR>Sai Parenterals Ltd was originally incorporated as 'Sai Parenteral's Private Limited' in 2001. The company transitioned to a Public Limited Company and changed its name to 'Sai Parenteral's Limited' on January 17, 2022. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 57 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 10 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 2,479 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 172.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.17 <BR>Return on Equity: 2.91% <BR>Price to Book: 5.04<BR><BR>Contact Details: <BR>No Company Details Available <BR>Registrar Address: Not available.

How big is Sai Parenteral's?

As of 10th June, Sai Parenterals Ltd has a market capitalization of 2,479.00 Cr, with recent Net Sales of 294.08 Cr and a Net Profit of 6.50 Cr for the quarters ending March 2026 and December 2025.

As of 10th June, Sai Parenterals Ltd has a market capitalization of 2,479.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest two quarters, the company reported Net Sales of 294.08 Cr and a Net Profit of 6.50 Cr. This reflects the financial performance for the quarters ending March 2026 and December 2025.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 93.67 Cr and Total Assets valued at 271.86 Cr.

Who are the peers of the Sai Parenteral's?

Sai Parenteral's peers include Unichem Labs, Novartis India, Solara Active, and others, with varying management risk and growth ratings. Venus Remedies leads in 1-year returns at 270.28%, while Dishman Carbogen has the lowest at -38.51%.

Peers: The peers of Sai Parenteral's are Unichem Labs., Novartis India, Solara Active, Dishman Carbogen, Morepen Labs., Kwality Pharma, Venus Remedies, Hikal, Indoco Remedies, and Sakar Healthcare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Novartis India, Venus Remedies, and the rest have Average management risk, including Unichem Labs., Morepen Labs., Kwality Pharma, Hikal, Indoco Remedies, and Sakar Healthcare. Below Average management risk is found at Solara Active and Dishman Carbogen. Growth is rated as Excellent for Novartis India, Venus Remedies, and Kwality Pharma, while Good growth is seen at Unichem Labs. and Dishman Carbogen. The rest, including Solara Active, Morepen Labs., Hikal, Indoco Remedies, and Sakar Healthcare, exhibit Below Average growth. Capital Structure is Excellent for Novartis India, Morepen Labs., and Kwality Pharma, while Good is seen at Unichem Labs. The rest, including Solara Active, Dishman Carbogen, Hikal, Indoco Remedies, and Sakar Healthcare, have Below Average capital structure.<BR><BR>Return Snapshot: Venus Remedies has the highest 1-year return at 270.28%, while Dishman Carbogen has the lowest at -38.51%. Sai Parenteral's 1-year return is not available for comparison. Additionally, Hikal and Dishman Carbogen have negative six-month returns.

When is the next results date for Sai Parenterals Ltd?

Sai Parenterals Ltd will announce its results on 23 May 2026.

Sai Parenterals Ltd is scheduled to declare its results on 23 May 2026.